{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:10:55Z","timestamp":1794471055749,"version":"4.9.1"},"reference-count":18,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hematotoxicity after chimeric antigen receptor (CAR) T-cell therapy is associated with infection and death but management remains unclear. We report results of 31 patients receiving hematopoietic stem cell boost (HSCB; 30 autologous, 1 allogeneic) for either sustained severe neutropenia of grade 4 (&amp;lt;0.5\u00a0\u00d7 109\/L), sustained moderate neutropenia (\u22641.5\u00a0\u00d7 109\/L) and high risk of infection, or neutrophil count \u22642.0\u00a0\u00d7 109\/L and active infection. Median time from CAR T-cell therapy to HSCB was 43 days and median absolute neutrophil count at time of HSCB was 0.2. Median duration of neutropenia before HSCB was 38 days (range, 7-151). Overall neutrophil response rate (recovery or improvement) was observed in 26 patients (84%) within a median of 9 days (95% confidence interval, 7-14). Time to response was significantly associated with the duration of prior neutropenia (P\u00a0=\u00a0.007). All nonresponders died within the first year after HSCB. One-year overall survival for all patients was 59% and significantly different for neutropenia (\u226438 days; 85%) vs neutropenia &amp;gt;38 days before HSCB (44%; P\u00a0= .029). In conclusion, early or prophylactic HSCB showed quick response and improved outcomes for sustained moderate to severe neutropenia after CAR-T.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008042","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T17:52:46Z","timestamp":1655142766000},"page":"555-559","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":59,"title":["Hematopoietic stem cell boost for persistent neutropenia after CAR\u00a0T-cell therapy: a GLA\/DRST study"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"first","affiliation":[{"name":"1Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald Georg","family":"Wulf","sequence":"additional","affiliation":[{"name":"2H\u00e4matologie und Medizinische Onkologie, UM G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Duell","sequence":"additional","affiliation":[{"name":"3Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[{"name":"4Klinik f\u00fcr H\u00e4matologie und Stammzelltransplantation, Helios Clinic Berlin-Buch, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"van Heteren","sequence":"additional","affiliation":[{"name":"4Klinik f\u00fcr H\u00e4matologie und Stammzelltransplantation, Helios Clinic Berlin-Buch, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Fischer","sequence":"additional","affiliation":[{"name":"2H\u00e4matologie und Medizinische Onkologie, UM G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Oncology, and Tumor Immunology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herrmann","family":"Einsele","sequence":"additional","affiliation":[{"name":"3Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine I, Leukapheresis and Stem Cell Transplant Unit, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Thomson","sequence":"additional","affiliation":[{"name":"2H\u00e4matologie und Medizinische Onkologie, UM G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"8Internal Medicine V - Hematology, Oncology & Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"2023081515544424900_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"10","key":"2023081515544424900_bib2","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"2023081515544424900_bib3","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"2023081515544424900_bib4","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021015209","article-title":"GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2023081515544424900_bib5","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2023081515544424900_bib6","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1002\/ajh.25664","article-title":"Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells","volume":"95","author":"Yan","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"2023081515544424900_bib7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41409-022-01570-4","article-title":"\u2018Save the day with a stem cell rescue\u2019: use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy","volume":"57","author":"Hashmi","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2023081515544424900_bib8","volume-title":"The EBMT handbook, Hematopoietic stem cell transplantation and cellular therapies","year":"2019","edition":"7th ed."},{"key":"2023081515544424900_bib9","author":"Kalbfleisch","year":"2002","edition":"2nd ed."},{"issue":"4","key":"2023081515544424900_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.26113","article-title":"Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies","volume":"96","author":"Nagle","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"2023081515544424900_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"2023081515544424900_bib12","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"21","key":"2023081515544424900_bib13","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023081515544424900_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023081515544424900_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2023081515544424900_bib16","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.bbmt.2020.04.025","article-title":"Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation","volume":"26","author":"Schubert","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2023081515544424900_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/bloodadvances.2021005788","article-title":"Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"key":"2023081515544424900_bib18","unstructured":"Lenz\n              G\n            , ChapuyB, GlassB, . Diffuse large B-cell lymphoma. Accessed 30 May 2022. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/diffuses-grosszelliges-b-zell-lymphom\/@@guideline\/html\/index.html#ID0EUDAE."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/4\/555\/2071369\/blooda_adv-2022-008042-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/4\/555\/2071369\/blooda_adv-2022-008042-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:57:51Z","timestamp":1692100671000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/4\/555\/485535\/Hematopoietic-stem-cell-boost-for-persistent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008042","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]}}}